Stoke Short Long Term Debt Total from 2010 to 2024

STOK Stock  USD 11.27  0.04  0.35%   
Stoke Therapeutics Short and Long Term Debt Total yearly trend continues to be quite stable with very little volatility. Short and Long Term Debt Total may rise above about 7.2 M this year. From the period between 2010 and 2024, Stoke Therapeutics, Short and Long Term Debt Total regression line of its data series had standard deviation of  2,430,056 and standard deviation of  2,430,056. View All Fundamentals
 
Short and Long Term Debt Total  
First Reported
2010-12-31
Previous Quarter
6.8 M
Current Value
7.2 M
Quarterly Volatility
2.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Stoke Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Stoke Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 9.2 M, Interest Income of 131.1 K or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 30.42, Dividend Yield of 0.0 or PTB Ratio of 1.52. Stoke financial statements analysis is a perfect complement when working with Stoke Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Stoke Therapeutics Correlation against competitors.
For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.

Latest Stoke Therapeutics' Short Long Term Debt Total Growth Pattern

Below is the plot of the Short Long Term Debt Total of Stoke Therapeutics over the last few years. It is Stoke Therapeutics' Short and Long Term Debt Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Stoke Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Short Long Term Debt Total10 Years Trend
Slightly volatile
   Short Long Term Debt Total   
       Timeline  

Stoke Short Long Term Debt Total Regression Statistics

Arithmetic Mean1,250,517
Geometric Mean221,326
Coefficient Of Variation194.32
Mean Deviation1,716,758
Median80,000
Standard Deviation2,430,056
Sample Variance5.9T
Range7.1M
R-Value0.71
Mean Square Error3.2T
R-Squared0.50
Significance0
Slope383,251
Total Sum of Squares82.7T

Stoke Short Long Term Debt Total History

20247.2 M
20236.8 M
20222.4 M
20211.5 M

About Stoke Therapeutics Financial Statements

Stoke Therapeutics investors utilize fundamental indicators, such as Short Long Term Debt Total, to predict how Stoke Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Short and Long Term Debt Total6.8 M7.2 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Stoke Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stoke Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Stoke Therapeutics Stock:
Check out the analysis of Stoke Therapeutics Correlation against competitors.
For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stoke Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.08)
Revenue Per Share
0.328
Quarterly Revenue Growth
0.479
Return On Assets
(0.28)
Return On Equity
(0.52)
The market value of Stoke Therapeutics is measured differently than its book value, which is the value of Stoke that is recorded on the company's balance sheet. Investors also form their own opinion of Stoke Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Stoke Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stoke Therapeutics' market value can be influenced by many factors that don't directly affect Stoke Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stoke Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.